ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1990

Treatment Of ACUTE Gout In The Emergency Department Evaluated According To The 2012 American College Of Rheumatology Guidelines

Naomi Schlesinger1, Tina Chang Young2, Diane C. Radvanski3, Dirk Moore4 and Robert Eisenstein5, 1Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 2Department of Biostatistics, UMDNJ/School of Public Health, Piscataway, NJ, 3Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, 4Department of Biostatistics, UMDNJ - School of Public Health, Piscataway, NJ, 5, Department of Emergency Medicine, UMDNJ- Robert Wood Johnson Medical School, New Brunswick, NJ

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: gout

  • Tweet
  • Email
  • Print
Session Information

Session Title: Metabolic and Crystal Arthropathies II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Acute gout attacks account for a substantial number of emergency department (ED)  visits.  Our aim was to record acute gout treatment in the ED and evaluate the treatment according to the 2012 American College of Rheumatology (ACR) guidelines (Khanna D et al.  Arthritis Care Res. 2012; 64:1447-61).  

Methods:

Retrospective chart review of consecutive patients with acute gout  seen in the  ED 1/01/2004 – 12/31/2010. Patients  included if  their diagnosis field included the word gout.   Variables included: age, years of gout, number of attacks/year, comorbidities, medications and involved joints.

Descriptive and summary statistics were performed on all variables. Subgroup analysis, sensitivity analysis and exploratory data performed where applicable.  

 Results:

541 acute gout patient visits recorded in the ED over 7 years. Mean patient age: 54 (range 20-96); 79% were men. 118 (22%): first attack.  75%: attack duration ≤ 3 days.  Most commonly affected: lower extremity joints.

Of  the 541 visits, 355 (66%) given drug treatment in the ED; 186 (34%) not given a medication during their visit.  Medications given: NSAIDs: 56 % (n=198): (toradol 19% (n=69); indomethacin 19% (n=66); Ibuprofen 14% (n=49); naproxen 3% (n=11)); opiates 54% (n=190); colchicine 9% (n= 32); prednisone 9% (n=32). 154 (28%) not given  drugs during  visit received prescriptions. 6% (n=32) given no drugs during visit nor did they receive a prescription.

An anti-inflammatory drug given during 44% (n=239) of visits.  75% (n=408) given an anti-inflammatory drug prescription.  40% (n=216) given an anti-inflammatory drug during visit and a prescription. 110 (20%)  not given an anti-inflammatory drug during visit nor a prescription. 

35% (n=190) given an opiate (oxycodone/acetaminophen) during the ED visit and 52% (n=282) a prescription. 

Monotherapy given during 74% (n=262) of  visits.  

During 13.4% (n=72) of  visits  patient reported being on colchicine prophylaxis. Patients on colchicine prophylaxis significantly more likely to receive colchicine for their acute attack than those not on prophylaxis (p=0.005).

Conclusion:

According to the ACR guidelines, first-line anti-inflammatory drugs for the treatment of acute gout include oral colchicine, NSAIDs and corticosteroids, yet during 56% of acute gout ED visits, anti-inflammatory drugs not given.  The ACR guidelines propose treatment be  continued for 7-10 days yet only 40%  given anti-inflammatory drugs in the ED and prescriptions. We suggest that 60% did not receive optimal treatment for  acute gout.  The ACR guidelines suggest  that colchicine is not recommended when attack occurred in a patient on  colchicine prophylaxis yet patients on chronic  prophylaxis  significantly more likely to receive colchicine for their acute attack. Opiates  commonly given in the ED for acute gout; however,  analgesia alone does not treat gouty inflammation (not addressed in  guidelines). Combination of colchicine and NSAIDs suggested for severe and unresponsive attacks by ACR guidelines, yet in 76% of patient visits receiving combination therapy, an opiate was combined with an NSAID or prednisone.

Further studies are needed for development of evidence-based guidelines tailored to the ED to help improve treatment of acute gout in the ED.


Disclosure:

N. Schlesinger,

Novartis Pharmaceutical Corporation,

2,

Novartis Pharmaceutical Corporation,Sobi,

5,

Novartis Pharmaceutical Corporation; Takeda, Savient,

8,

Novartis Pharmaceutical Corporation, Takeda, Savient, Sobi,

9;

T. Chang Young,
None;

D. C. Radvanski,
None;

D. Moore,
None;

R. Eisenstein,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-acute-gout-in-the-emergency-department-evaluated-according-to-the-2012-american-college-of-rheumatology-guidelines/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences